Successful treatment of systemic lupus erythematosus with residual disease activity by switching from belimumab to anifrolumab.

导出 LinkOut

翻译打印收藏纠错

第一作者： Masataka,Umeda

第一单位： Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.;Research Unit for Preventive and Clinical Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

作者： Masataka,Umeda ^[1] ; Kanako,Kojima ^[2] ; Toru,Michitsuji ^[2] ; Yoshika,Tsuji ^[2] ; Toshimasa,Shimizu ^[2] ; Shoichi,Fukui ^[2] ; Remi,Sumiyoshi ^[2] ; Tomohiro,Koga ^[2] ; Shin-Ya,Kawashiri ^[2] ; Iwamoto,Naoki ^[2] ; Takashi,Iagawa ^[2] ; Mami,Tamai ^[2] ; Tomoki,Origuchi ^[2] ; Masako,Furuyama ^[3] ; Masahiko,Tsuboi ^[4] ; Naoki,Matsuoka ^[4] ; Akitomo,Okada ^[5] ; Toshiyuki,Aramaki ^[6] ; Atsushi,Kawakami ^[1]

作者单位： Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.;Research Unit for Preventive and Clinical Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. ^[1] Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. ^[2] Department of Rheumatology, Nagasaki Kita Hospital, Nagasaki, Japan. ^[3] Nagasaki Medical Hospital of Rheumatology, Nagasaki, Japan. ^[4] Department of Rheumatology, National Hospital Organization Nagasaki Medical Center, Omura, Japan. ^[5] Department of Rheumatology, Sasebo Chuo Hospital, Sasebo, Japan. ^[6]

关键词 Anifrolumab belimumab biologics systemic lupus erythematosus treatment switching

主题词人类(Humans);药物替代(Drug Substitution);免疫抑制剂(Immunosuppressive Agents);红斑狼疮, 系统性(Lupus Erythematosus, Systemic);治疗结果(Treatment Outcome)

DOI 10.1093/mr/roae038

PMID 38756072

发布时间 2025-02-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交